about the author

Endpoints Contributor

help@endpts.com

author articles

Un­lock­ing ESG strate­gies for growth with Gilead Sci­ences

4 years ago

In­side Track: Be­hind the Scenes of a Ma­jor Biotech SPAC

4 years ago

How Mul­ti-Stake­hold­er Strate­gies for Ex­ter­nal Con­trol Arms Can Over­come Ap­proval and Ac­cess Bar­ri­ers

4 years ago

Mov­ing Out of the Clin­ic with Dig­i­tal Tools: Mo­bile Spirom­e­try Dur­ing COVID-19 & Be­yond

4 years ago

How Pa­tients with Epilep­sy Ben­e­fit from Re­al-World Da­ta

4 years ago

The DCT-OS: A Tech­nol­o­gy-first Op­er­at­ing Sys­tem - En­abling Clin­i­cal Tri­als

5 years ago

We need faster end­points for tar­get­ed can­cer drugs – here’s one we can use

5 years ago

Qual­i­ty Con­trol in Cell and Gene Ther­a­py – What’s Re­al­ly at Stake?

5 years ago

The right to vote is fun­da­men­tal — a let­ter from biotech­nol­o­gy in­dus­try lead­ers

5 years ago
People
Biotech Voices

BY­OD Best Prac­tices: How Mo­bile De­vice Strat­e­gy Leads to More Pa­tient-Cen­tric Clin­i­cal Tri­als

5 years ago

Can we cre­ate a world free of pain?

5 years ago

The con­tin­u­ing CRISPR patent saga

5 years ago
Biotech Voices

Start­ing your clin­i­cal jour­ney with the end in mind – the val­ue of a drug de­vel­op­ment plan

5 years ago

From Clin­i­cal Strat­e­gy to De­vel­op­ment: Nav­i­gat­ing COVID-19 to Sup­port the Next Gen­er­a­tion of Pa­tient-Fo­cused ...

5 years ago

Top Five Rules for Suc­cess in De­cen­tral­ized Tri­als

5 years ago

Ac­cel­er­at­ing drug de­vel­op­ment with­out sac­ri­fic­ing safe­ty: How phar­ma­covig­i­lance is keep­ing pace with COVID-19 ...

5 years ago

How we are stay­ing con­nect­ed when we’re apart

5 years ago
Biotech Voices

The path to NASH: un­der­stand­ing the role of se­vere obe­si­ty in a com­plex, mul­ti-sys­tem dis­ease

5 years ago
Biotech Voices

In­dus­try lead­ers need to speak out now more than ever

5 years ago
Biotech Voices

Tar­get­ing a Po­ten­tial Vul­ner­a­bil­i­ty of Cer­tain Can­cers with DNA Dam­age Re­sponse

5 years ago

Forg­ing an In­no­v­a­tive Path in CNS Treat­ment

5 years ago

Why mu­cos­al im­mu­ni­ty may be re­quired to end the pan­dem­ic

5 years ago
Biotech Voices

Is Aus­tralia the next Glob­al Des­ti­na­tion for Phase 2?

5 years ago

How will the Biden ad­min­is­tra­tion af­fect fund­ing for life sci­ence re­search?

5 years ago
Biotech Voices
First page Previous page 45678910 Next page Last page
A service from the Financial Times